参考文献/References:
[1] Teng R. Ticagrelor:pharmacokinetic,pharmacodynamic and pharmacogenetic profile:an update[J]. Clin Pharmacokinet,2015,54(11):1125-1138.
[2] Becker RC,Bassand JP,Budaj A,et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and Patient Outcomes (PLATO) trial[J]. Eur Heart J,2011,32(23):2933-2944.
[3] Bonaca MP,Bhatt DL,Cohen M,et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med,2015,372(19):1791-1800.
[4] Steg PG,Bhatt DL,Simon T,et al. Ticagrelor in patients with stable coronary disease and diabetes[J]. N Engl J Med,2019,381(14):1309-1320.
[5] Bhatt DL,Steg PG,Mehta SR,et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI):a phase 3,placebo-controlled,randomised trial[J]. Lancet,2019,394(10204):1169-1180.
[6] Park DW,Lee PH,Jang S,et al. Effect of low-dose versus standard-dose ticagrelor and clopidogrel on platelet inhibition in acute coronary syndromes[J]. J Am Coll Cardiol,2018,71(14):1594-1595.
[7] Teng R,Butler K. Pharmacokinetics,pharmacodynamics,and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers[J].Int J Clin Pharmacol Ther,2014,52(6):478-491.
[8] Teng R,Butler K. Pharmacokinetics,pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor,a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects[J]. Eur J Clin Pharmacol,2010,66(5):487-496.
[9] Li P,Gu Y,Yang Y,et al. Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects:an open-label randomized controlled trial[J]. Sci Rep,2016,6:31838
[10] Storey RF, Angiolillo DJ,Bonaca MP,et al. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial[J]. J Am Coll Cardiol,2016,67(10):1145-1154.
[11] Kubica J,Adamski P,Buszko K,et al. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction(ELECTRA):a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study[J]. Eur Heart J Cardiovasc Pharmacother,2019,5(3):139-148.
[12] 闫伟国.围手术期新型抗血小板及抗凝药物管理[J].心血管病学进展,2018,39(5):776-780.
[13] Teng R,Oliver S,Hayes MA,et al. Absorption,distribution,metabolism,and excretion of ticagrelor in healthy subjects[J]. Drug Metab Dispos,2010,38(9):1514-1521.
相似文献/References:
[1]陈艳,综述,袁晋青,等.替格瑞洛临床应用新进展[J].心血管病学进展,2016,(3):235.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.005]
CHEN Yan,YUAN Jinqing.The Updates of Ticagrelor Use in Clinical Practice[J].Advances in Cardiovascular Diseases,2016,(7):235.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.005]
[2]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(7):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[3]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(7):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[4]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(7):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[5]周锐 赵飞飞 钱阳 余文静 王大新..氯吡格雷与替格瑞洛的安全性和有效性在东亚急性心肌梗死患者的比较：系统回顾和荟萃分析[J].心血管病学进展,2021,(6):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
ZHOU RuiZHAO Feifei QIAN YangYU WenjingWANG Daxin.Comparison of the Safety and Efficacy of Clopidogrel Versus Ticagrelor in Patients with Acute Myocardial Infarction in East Asia:a Systematic Review and Meta-Analysis[J].Advances in Cardiovascular Diseases,2021,(7):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
[6]王晓妍 崔炜.替格瑞洛治疗急性冠脉综合征时引起缓慢性心律失常的研究进展[J].心血管病学进展,2021,(7):642.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.016]
WANG Xiaoyan,CUI Wei.Bradyarrhythmia Caused by Ticagrelor in Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(7):642.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.016]